Agenus (NASDAQ:AGEN) Earns Sell (D-) Rating from Weiss Ratings

Agenus (NASDAQ:AGEN)‘s stock had its “sell (d-)” rating reissued by equities researchers at Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

Several other research analysts also recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $23.00 target price on shares of Agenus in a report on Wednesday, September 10th. Wall Street Zen downgraded shares of Agenus from a “buy” rating to a “hold” rating in a report on Sunday, August 17th. Finally, Zacks Research raised shares of Agenus to a “hold” rating in a report on Tuesday, August 12th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $14.50.

Agenus Stock Performance

Shares of Agenus stock opened at $4.25 on Wednesday. The company has a market capitalization of $135.41 million, a P/E ratio of -0.59 and a beta of 1.43. The company has a fifty day moving average of $4.45 and a 200 day moving average of $4.11. Agenus has a fifty-two week low of $1.38 and a fifty-two week high of $7.34.

Agenus (NASDAQ:AGEN) last issued its earnings results on Monday, August 11th. The biotechnology company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.78) by ($0.22). The company had revenue of $25.70 million for the quarter, compared to the consensus estimate of $49.71 million. Analysts forecast that Agenus will post -12.55 EPS for the current year.

Institutional Trading of Agenus

Several hedge funds have recently bought and sold shares of AGEN. Catalyst Funds Management Pty Ltd purchased a new stake in shares of Agenus during the 2nd quarter valued at about $50,000. Jump Financial LLC purchased a new stake in shares of Agenus during the 2nd quarter valued at about $55,000. Savant Capital LLC purchased a new stake in shares of Agenus during the 2nd quarter valued at about $73,000. Bank of Montreal Can purchased a new stake in shares of Agenus during the 2nd quarter valued at about $75,000. Finally, Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Agenus during the 2nd quarter valued at about $85,000. Hedge funds and other institutional investors own 61.46% of the company’s stock.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.